CRMG Company Profile

& RESEARCH EXPERIENCE

Present Administrative Staff

Medical Director/Principal Investigator, CRMG, Inc.	**Dr. Javier Sosa Faria**
President of Operations, CRMG, Inc.	**Mario Franceschi**
Vice- President, CRMG, Inc.	**Yanira Franceschi**
Sr. Coordinator, CRMG, Inc	**Jailine Fraticelli**

Contact Numbers

- **Administration Service (787) 955-0800**
- **Accounting & Billing (787) 718-3130**
- **Operations & Clinical (787) 354-4420**

Research Site-Affiliations & Medical Specialties

- **Main Administrative Office: Urb. Jardines de San Domingo Calle 5 A-18 Juana Juana Diaz PR 00795**

Medical facilities	Number of Professionals
Hospitals	**2**
Outpatient Hospital Clinics	**6**
Dialysis Centers	**2**
Infusion Centers	**2**
Emergency Room	**8**
Medical Offices	**14**
Oncology Infusion Centers	**2**

CRMG Medical Specialty	Number of Professionals
Nephrologist	**3 New**
Cardiologist	**2**
Internal Medicine	**2**
Pediatrician	**2**
Otolaryngologist	**1**
Pulmonologist	**1**
Gastroenterologist	**2**
General Practitioner	**4**
Oncologist	**2**

Company Work & Research Experience

- **(Motif Biosciences Inc.) - A Phase 3, randomized, double-blinded, multicenter study to evaluate the safety and efficacy of intravenous Iclaprim versus Vancomycin in the treatment of acute bacterial skin and skin structure infections suspected or confirmed o be due to Gram-positive pathogens. (Revive 1)**

- **(Gliknik Inc, Company) - A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (with Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+Patients with High-Risk Squamous Cell Carcinoma of the Oral Cavity.**

- **(Motif Biosciences Inc.) - A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin structure infections suspected or confirmed to be due to Gram-positive pathogens.**

- **(Kyowa Pharmaceutical) - A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy and Long-term Extension Therapy) of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects with Moderately Active Ulcerative Colitis.**

- **(Boehringer Ingelheim Pharmaceutical) - Randomized, double-blind, placebo-controlled trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of 4 multiple rising oral doses of BI 685509 over 28 days in male and female patients with diabetic nephropathy**

- **(Factor Therapeutic Ltd) - A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial Comparing Two Doses of VF001-DP to Placebo as an Adjunct to Standard Care (SC) in Patients with Chronic Venous Leg Ulcers (VLUs)**

- **(Emergent BioSolutions) - A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating the Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients with Serious Influenza A Infection**

- **(Romark Global Pharma LCC.) - A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza.**

- **(Romark Global Pharma LCC.) - A Phase 3, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Colds due to Enterovirus/Rhinovirus Infection.**

- **(Serena Group) - A Randomized Controlled Multicenter Trial, Examinating the Effect of Natrox Oxygen Wound Therapy on the Healing Rate of Chronic Diabetic Foot Ulcers (NOW.T-001)**

- **(Serena Group) Efficacy of TR 987, beta-1,3-1,6-D-glucan, in the treatment of chronic venous insufficiency ulcers: a two-arm, double blind, placebo controlled, randomized controlled trial. (BG001)**

- **(Eli Lilly & Company) - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and ActiveControlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease**

- **(Serena Group) - A Randomized Controlled Double-Blind Multi-Center Clinical Trial Evaluating Remote Ischemic Conditioning and Standard of Care vs Sham Therapy and Standard Care in the Healing of Diabetic Foot Ulcers**

- **(Serena Group) - A Randomized Controlled Multicenter Clinical Trial, Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®) and Standard of Care versus Standard of Care alone in the healing Chronic Diabetic Foot Ulcers**

- **(Romark Global Pharma LCC.) - A Randomized, Double-Blind, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) For Post-Exposure Prophylaxis Of COVID-19 And Other Viral Respiratory Illnesses (VRI) In Healthcare Workers**

- **(Romark Global Pharma LCC.) - Phase 3, Randomized, Double-Blind, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of Nitazoxanide In the Treatment Of Mild Or Moderate COVID-19**

- **(CalciMedcia Biotechnology Company) - A Randomized Double Blind, Placebo-Controlled Study of Auxora for the Treatment of Severe COVID-19 Pneumonia (CARDEA)**

- **(Bristol-Myers Squibb) - Phase 2, Randomized, Double-Blind Placebo Controlled Study of Intravenous Abatacept in the Treatment of Hospitalized COVID-19 Participants with Respiratory Compromise**

- **(Pfizer Pharmaceutical) - A Phase 2/3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and pharmacokinetics of orally administered PF 07321332/ritonavir in non-hospitalized adult participants with COVID-19 at low risk of progressing to severe disease**

- **(Pfizer Pharmaceutical) - A Phase 2/3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and pharmacokinetics of orally administered PF-07321332/ritonavir in non-hospitalized adult participants with COVID-19 at high risk of progressing to severe disease**

- **(Pfizer Pharmaceutical) - A Phase 2/3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered PF-07321332 in preventing SARS-CoV-2 infection in household contacts of individuals infected with SARS-CoV-2.**

- **(Eli Lilly & Company) - A Phase 2 Study of Once Daily LY3502970 Compared with Placebo and Once Weekly Dulaglutide in Participants with Type 2 Diabetes Mellitus**

- **(AstraZeneca Pharmaceutical) - A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide,**

Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)